Pomerantz Law Firm Investigates Replimune Group, Inc. for Potential Securities Fraud
Pomerantz LLP is investigating Replimune Group, Inc. (NASDAQ: REPL) for potential securities fraud following the company's receipt of a complete response letter from the FDA regarding its Biologics License Application. The stock price of Replimune fell significantly after the announcement, indicating a strong market reaction to the news.
Tickers: $REPL
Topics: biologics license application class action FDA securities fraud stock price drop